Contribution of CYP3A Isoforms to Dealkylation of PDE5 Inhibitors: A Comparison between Sildenafil N-Demethylation and Tadalafil Demethylenation-Reference-Cited by-同舟云学术

Contribution of CYP3A Isoforms to Dealkylation of PDE5 Inhibitors: A Comparison between Sildenafil N-Demethylation and Tadalafil Demethylenation

Published:2015 Issue:1 Volume:38 Page:58-65
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Takahiro Rikako¹,Nakamura Saki¹,Kohno Hiroyuki¹,Yoshimura Naoki²,Nakamura Tsuneyuki³,Ozawa Sayaka⁴,Hirono Keiichi⁴,Ichida Fukiko⁴,Taguchi Masato¹

Affiliation:

1. Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama

2. First Department of Surgery, Faculty of Medicine, University of Toyama

3. Department of Pediatrics, Kanazawa Medical University

4. Department of Pediatrics, Faculty of Medicine, University of Toyama

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/38/1/38_b14-00566/_pdf

Reference30 articles.

1. 1) Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ. Res., 93, 280–291 (2003).

2. 2) Lewis GD, Semigran MJ. Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension. Curr. Heart Fail. Rep., 1, 183–189 (2004).

3. 3) Takatsuki S, Calderbank M, Ivy DD. Initial experience with tadalafil in pediatric pulmonary arterial hypertension. Pediatr. Cardiol., 33, 683–688 (2012).

4. 4) Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadas B, Schermuly RT, Weissmann N, Seeger W, Grimminger F. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J. Am. Coll. Cardiol., 44, 1488–1496 (2004).

5. 5) Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br. J. Clin. Pharmacol., 53 (Suppl. 1), 5S–12S (2002).

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytochrome P450-mediated metabolic interactions between donepezil and tadalafil in human liver microsomes;Toxicology in Vitro;2024-10

2. Prediction of Pediatric Pharmacokinetics for CYP3A4 Metabolized Drugs: Comparison of the Performance of Two Hepatic Ontogeny Within a Physiologically Based Pharmacokinetic Model;The Journal of Clinical Pharmacology;2024-05-02

3. Physiologically Based Pharmacokinetics Modeling in the Neonatal Population—Current Advances, Challenges, and Opportunities;Pharmaceutics;2023-11-03

4. Breast Cancer Resistance Protein Limits Fetal Transfer of Tadalafil in Mice;Journal of Pharmaceutical Sciences;2023-11

5. Use of Developmental Midazolam and 1-Hydroxymidazolam Data with Pediatric Physiologically Based Modeling to Assess Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyl Transferase 2B4 Ontogeny In Vivo;Drug Metabolism and Disposition;2023-05-11